The female infertility market is anticipated to experience moderate expansion, with revenue increasing from $1.6 billion in 2023 to $2.3 billion by 2033. This growth reflects a compound annual growth rate (CAGR) of 3.5% across the seven major markets (7MM), which include the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan, as outlined in GlobalData’s latest report, Female Infertility: Seven Market Drug Forecast and Market Analysis.
The primary driver of this market growth is the rising number of women deferring pregnancy until later in life, a factor that typically results in decreased fertility with age. Additionally, new therapies are expected to contribute modestly to market expansion during the forecast period. Notable pipeline drugs anticipated to enter the market include Kissei Pharmaceutical’s linzagolix choline, IBSA Institut Biochimique’s subcutaneous progesterone, and Ferring Pharmaceuticals’s Menopur (menotropin).
Despite these advancements, the female infertility market remains competitive, with a limited number of major players and a significant reliance on off-label treatments. Many of the drugs used in fertility treatments are originally indicated for conditions such as breast cancer and other gynecological disorders, which presents a considerable challenge for the introduction of novel therapies.
Current treatments for female infertility have seen little change, with Merck Sereno’s Gonal-F continuing to lead the market. Forecasts project Gonal-F’s sales to reach $713 million by 2033. Key opinion leaders interviewed by GlobalData note a moderate level of unmet need in this sector. There is a notable demand for improved IVF processes, particularly in simplifying the route of administration and dosing frequency of the various drugs involved.
Among the 7MM markets, the United States stands out as the largest contributor to the female infertility market, accounting for 58.5% of sales in 2023 and expected to rise to 66.0% by 2033. This dominance is attributed to the higher cost of therapeutics and a greater prevalence of female infertility in the U.S. Conversely, Spain is projected to have the smallest market share, contributing 4.5% of sales in 2023 and 4% by 2033.
Related topics:
